explore -WSS

explore

author：hotspot 2025-09-02 22:22:51 - browse：283

Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.

The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.

RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Trump's false claims about Georgia's 2020 election long debunked

Wikipedia

WSS

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

As Maui death toll rises, number of missing remains unclear

Why CTE doesn’t keep Americans from enjoying the Super Bowl

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Adopting new red light myopia treatments may be short

Why Novartis is going to walk from its acquisition of MorphoSys

focus

explore

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Majority of Americans think Trump's Ga. election interference case is serious: POLL

In Memoriam: Notable people who died in 2023

An interview with Robert F. Kennedy Jr. on vaccines

Medicare details structure of new drug price negotiation program

Trump's false claims about Georgia's 2020 election long debunked

Anesthesiologist group: stop taking Ozempic before surgery

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

State Dept. review finds Biden bears some blame for Afghanistan failures

Bernie brings in new pharma CEOs to talk drug prices

focus

FDA approves first treatment for ultra

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Baltimore teen accused of firing into crowd during block party mass shooting

AstraZeneca stays mum on Medicare drug pricing negotiations

New definition of a human embryo proposed amid rapid advances

The Biogen Aduhelm mess could happen again

hotspot

Wikipedia

focus

Wikipedia